Fungal infection in the lung transplant recipient

Clinical Pulmonary Medicine

Volumn 8, Issue 3, 2001, Pages 123-133

  Peters, Jay I ^a,b   Levine, Stephanie M ^a  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Amphotericin B; Aspergillus; Azole agents; Candida; Lung transplant

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; IBUPROFEN; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PARACETAMOL; PETHIDINE; PYRROLE DERIVATIVE; SCH 56692; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTHRALGIA; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CHEMOPROPHYLAXIS; CHILL; DRUG COST; DRUG INDICATION; FEVER; HEADACHE; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; LUNG TRANSPLANTATION; MYALGIA; MYCOSIS; NAUSEA; POSTOPERATIVE INFECTION; REVIEW; RIGOR; RISK FACTOR; VOMITING;

EID: 0034996635     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045413-200105000-00002     Document Type: Review

References (73)

1. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report-1999. J Heart Lung Transplant. 1999;18: 611-626.
2. Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2000; 2:1-7.
3. Paya CV. Fungal infection in solid-organ transplantation. Clin Infect Dis. 1993;16:677-688.
4. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med. 1990;11:291-308.
5. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Medicine (Baltimore). 1996;75:142-156.
6. Patterson DL, Singh N. Fungal infections complicating transplantation. In: Sarosi GA, Davies SF, eds. Fungal Diseases of the Lung. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:239-269.
7. Paradowski LJ. Saprophytic fungal infections and lung transplantation-revisited. J Heart Lung Transplant. 1997;16:524-531.
8. Flume PA, Egan TM, Paradowski LJ, et al. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med. 1994;149:1601-1607.
9. Yeldandi V, Laghi F, McCabe MA, et al. Aspergillus and lung transplantation. J Heart Lung Transplant. 1995;14:883-890.
10. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160-1164.
11. Westney GE, Kesten S, De Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61: 915-919.
12. Guillemain R, Lavarde V, Amrein C, et al. Invasive aspergillosis after transplantation. Transplant Proc. 1995;27:1307-1309.
13. Bertocchi M, Thevenet F, Bastien O, et al. Fungal infections in lung transplant recipients. Transplant Proc. 1995;27:1695.
14. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998;26:753-755.
15. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis. Am Rev Respir Dis. 1991;144:552-556.
16. Chaparro C, Chamberlain D, Maurer J, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients. Chest. 1996;110:1150-1154.
17. Shreeniwas R, Schulman LL, Berkmen YM, et al. Opportunistic bronchopulmonary infections after lung transplantation: clinical and radiographic findings. Radiology. 1996;200: 349-356.
18. Diederich S, Scadeng M, Dennis C, et al. Aspergillus infection of the respiratory tract after lung transplantation: chest radiographic and CT findings. Eur Radiol. 1998;8:306-312.
19. Tazelaar HD, Baird AM, Mill M, et al. Bronchocentric mycosis occurring in transplant recipients. Chest. 1989;96:92-95.
20. Susanto I, Peters JI, Levine SM, et al. Use of balloon expandable metallic stents in the management of bronchial stenosis and bronchomalacia after lung transplantation. Chest. 1998; 114:1330-1135.
21. Egan JJ, Yonan N, Carroll KB, et al. Allergic bronchopulmonary aspergillosis in lung allograft recipients. Eur Respir J. 1996;9:169-171.
22. Pomerance A, Madden B, Burke MM, et al. Transbronchial biopsy in heart and lung transplantation: clinicopathologic correlations. J Heart Lung Transplant. 1995;14:761-773.
23. Brenier-Pinchart M-P, Lebeau B, Devoussoux G, et al. Aspergillus and lung transplant recipients: a mycologic and molecular epidemiologic study. J Heart Lung Transplant. 1998;17: 972-979.
24. Tomee JFC, Mannes GPM, van der Bij W, et al. Serodiagnosis and monitoring of Aspergillus infections after lung transplantation. Ann Intern Med. 1996;125:197-201.
25. Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 1998;114:1321-1329.
26. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/ American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med. 1998;158: 335-339.
27. Palmer SM, Perfect JR, Howell DN, et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant. 1998;17:1029-1033.
28. DeCruyenaere J, Colardyn F, Vogelaers D, et al. Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Transplant Proc. 1995;27:3515-3516.
29. Tam JY, Hamed KA, Blume K, et al. Use of itraconazole in treatment of prevention of invasive aspergillosis in bone marrow transplant recipients. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC; 1993. Abstract 813.
30. Reichenspurner H, Gambert P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc. 1997;29: 627-628.
31. Trigg ME, Morgan D, Burns TL, et al. Successful program to prevent Aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin. Bone Marrow Transplant. 1997;19:43-47.
32. Conneally E, Cafferkey MT, Daly PA, et al. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 1990; 5:403-406.
33. Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemotlier. 1997;41:259-261.
34. Terrell CL, Hughes MD. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc. 1992;67:69-91.
35. Oldfield EC, Garst PD, Hostettler C, et al. Randomized doubleblind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother. 1990;34:1402-1406.
36. Hoeprich PD. Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis. 1992;14(suppl 1):S114-S119.
37. Groll AH, Walsh TJ. Polyene antifungal agents. In: Sarosi GA, Davies SF, eds. Fungal Diseases of the Lung. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:271-295.
38. Walsh TJ, Gonzalez C, Lyman C, et al. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis. 1996;11:187-290.
39. Arning M, Kliche KO, Heer-Sonderhoff AH, et al. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses. 1995;38: 459-465.
40. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6:154-164.
41. Heidemann HT, Gerkens JF, Spickard WA, et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med. 1983;75: 476-481.
42. White MH, Bowden RA, Sandier E, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empiric treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296-302.
43. Butler WT. Pharmacology, toxicology and therapeutic usefulness of amphotericin B. JAMA. 1966;195:127-131.
44. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998;27: 603-618.
45. Walsh TJ, Hiemenz JW, Seibel N, et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. In: Proceedings and abstracts of the 13th Congress of the International Society for Human and Animal Mycology, Parma, Italy; 1997. Abstract 571.
46. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22:315-321.
47. Anaissie EJ, White MH, Uzun O, et al. Amphotericin B lipid complex vs amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial . In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco), Washington, DC, American Society for Microbiology; 1994:330. Abstract LM21.
48. Oravcova E, Mistrik M, Sakalova A, et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy. 1995;41:473-476.
49. Mehta J, Chu P, Powles R, et al. Amphotericin B lipid complex for the treatment of presumed or confirmed fungal infections in immunocompromised patients with hematologic malignancies. Drugs Today. 1996;32:417-421.
50. Naguib MT, Huycke MM, Pederson JA, et al. Apophysomyces elegans infection in a renal transplant recipient. Am J Kidney Dis. 1995;26: 175-177.
51. Hospenthal DR, Byrd JC, Weiss RB. Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex. Med Pediatr Oncol. 1995;25:119-122.
52. Jones RS, Barman A, Suh B, et al. Successful treatment of Aspergillus vertebral osteomyelitis with amphotericin B lipid complex. Infect Dis Clin Pract. 1995;4:237-239.
53. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis: therapy with amphotericin B lipid complex. Arch Intern Med. 1996; 156:337-339.
54. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. In: Proceedings and abstracts of the 37th Annual Meeting and Exposition of the American Society of Hematology (Seattle), 1995; Abstract 3383.
55. Walker RC, Hiemenz JW. Amphotericin B lipid complex (ABLC) in systemic mycoses refractory to amphotericin B. In: Proceedings and abstracts of the 31st Annual Meeting of the American Society of Clinical Oncology (Los Angeles), 1995; Abstract 1724.
56. Hiemenz JW, Anaissie EJ, Walsh TJ. Amphotericin B lipid complex for the treatment of severe systemic mycosis in patients with hematologic malignancies. In: Proceedings and abstracts of the 36th Annual Meeting and Exposition of the American Society of Hematology (Nashville), 1994; Abstract 1207.
57. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997;24:635-642.
58. Chopra R, Blair S, Strang J, et al. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother. 1991;28(suppl B):93-104.
59. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy of invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med. 1995; 155:1093-2008.
60. Ringden O, Tollemar J, Dahllof G, et al. High cure rate of invasive fungal infections in immunocompromised children using AmBisome. Transplant Proc. 1994;26:175-177.
61. Leenders ACAP, Reiss P, Portegies P, et al. A randomized trial of liposomal amphotericin B (AmBisome) 4 mg/kg vs amphotericin B 0.7 mg/kg for cryptococcal meningitis in HIV-infected patients. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans), Washington, DC: American Society for Microbiology; 1996:287. Abstract LM35.
62. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764-771.
63. Verweij PE, Donnelly JP, Kullberg BJ, et al. Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection. 1994;22:81-85.
64. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994;331:1325-1330.
65. Sugar AM. Azole antifungals. In: Sarosi GA, Davies SF, eds. Fungal Diseases of the Lung. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:297-301.
66. McWhinney PHM, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis. 1993;17:397-401.
67. Saraceno JL, Phelps DT, Ferro TJ, et al. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest. 1997;112:541-548.
68. Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy. 1982;28:461-479.
69. Calliot D, Casanovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147.
70. Robinson LA, Reed EC, Galbraith TA, et al. Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. J Thorac Cardiovasc Surg. 1993;109:1182-1197.
71. Wong A, Waters CM, Walesby RK. Surgical management of invasive pulmonary aspergillosis in immunocompromised patients. Eur J Cardiothorac Surg. 1992;6:138-143.
72. Catalano L, Fontana R, Scarpato N, et al. Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Haematologica. 1997;82: 71-72.
73. Nemuniatis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinant human macrophage colonystimulating factor in patients with invasive fungal infections. Blood. 1991;78:907-913.